These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6429333)

  • 1. Troponoids. 6. Troponylpiperazines: a new class of dopamine agonists.
    Bagli J; Bogri T; Voith K
    J Med Chem; 1984 Jul; 27(7):875-81. PubMed ID: 6429333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troponoids. 7. Chemistry and dopamine agonist activity of ciladopa and related aralkyltroponylpiperazines.
    Bagli J; Bogri T; Voith K; Lee D
    J Med Chem; 1986 Feb; 29(2):186-93. PubMed ID: 3950903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug design via pharmacophore identification. Dopaminergic activity of 3H-benz[e]indol-8-amines and their mode of interaction with the dopamine receptor.
    Asselin AA; Humber LG; Voith K; Metcalf G
    J Med Chem; 1986 May; 29(5):648-54. PubMed ID: 3084784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
    Kenny AM; Schneider MB; Baden DR; Pfeiffer RF; Murrin LC
    Neurology; 1986 Mar; 36(3):400-4. PubMed ID: 3081831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment with bromocriptine induces behavioral supersensitivity in rats.
    Hassan MN; Higgins D; Traub M; Fahn S
    Life Sci; 1986 Aug; 39(6):513-8. PubMed ID: 3090394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways.
    Reavill C; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Mar; 32(5):865-70. PubMed ID: 6301501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 6-hydroxydopamine-induced selective parkinsonian rat model.
    Perese DA; Ulman J; Viola J; Ewing SE; Bankiewicz KS
    Brain Res; 1989 Aug; 494(2):285-93. PubMed ID: 2528389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated stimulation of D-1 dopamine receptors increases the circling response to bromocriptine in rats with a 6-OHDA lesion.
    Rouillard C; Bédard P; Falardeau P; Di Paolo T
    Eur J Pharmacol; 1988 Nov; 157(2-3):125-33. PubMed ID: 2975996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D1- and D2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats.
    Karlsson G; Jaton AL; Vigouret JM
    Neurosci Lett; 1988 May; 88(1):69-74. PubMed ID: 2969468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible decrease in dopaminergic 3H-agonist binding after 6-hydroxydopamine and irreversible decrease after kainic acid.
    Schweitzer BI; Bacopoulos NG
    Life Sci; 1983 Jan; 32(5):531-40. PubMed ID: 6296593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and antitumor activity of tropolone derivatives. 5.
    Yamato M; Hashigaki K; Sakai J; Takeuchi Y; Tsukagoshi S; Tashiro T; Tsuruo T
    J Med Chem; 1987 Jul; 30(7):1245-8. PubMed ID: 3599030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 6-hydroxydopamine-induced lesions of A10 dopaminergic neurons and neuroleptic or bromocriptine treatment on ethanol withdrawal syndrome in rats.
    Trzaskowska E; Puciłowski O; Kostowski W; Bidziński A
    Pol J Pharmacol Pharm; 1983; 35(5):339-49. PubMed ID: 6141554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.
    Yoshimura N; Kuno S; Chancellor MB; De Groat WC; Seki S
    Br J Pharmacol; 2003 Aug; 139(8):1425-32. PubMed ID: 12922929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat.
    Graham WC; Crossman AR; Woodruff GN
    Brain Res; 1990 Apr; 514(1):93-102. PubMed ID: 2113410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway.
    Duvoisin RC; Heikkila RE; Manzino L
    Neurology; 1982 Dec; 32(12):1387-91. PubMed ID: 6128698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troponoids. 3. Synthesis and antiallergy activity of N-troponyloxamic acid esters.
    Bagli JF; Bogri T; Palameta B; Martel R; Robinson W; Pugsley T; Lippmann W
    J Med Chem; 1979 Oct; 22(10):1186-93. PubMed ID: 229222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats.
    Ljungberg T; Ungerstedt U
    Physiol Behav; 1976 Mar; 16(3):277-83. PubMed ID: 1033572
    [No Abstract]   [Full Text] [Related]  

  • 20. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.